• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

Teva stock soars on positive Phase 2b study results

by December 17, 2024
written by December 17, 2024

Investing.com — Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) surged 17% following the announcement of successful Phase 2b study results for its investigational drug duvakitug, which is being developed to treat inflammatory bowel disease (IBD). The study, conducted in collaboration with Sanofi (NASDAQ:SNY), met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD), offering hope for a new treatment option in a field with high unmet medical needs.

The RELIEVE UCCD study showed that a significant portion of patients with UC and CD treated with duvakitug achieved clinical remission or endoscopic response at week 14 compared to those on placebo. The stock movement reflects investor optimism on the drug’s potential market impact, as the treatment effect was consistent across subgroups. Teva’s shares jumped 17% in response to the news.

Eric Hughes, MD, PhD, Head of Global R&D and Chief Medical (TASE:PMCN) Officer at Teva, expressed confidence in the study’s results and the potential benefits for patients living with IBD. Houman Ashrafian, MD, PhD, Executive Vice President, Head of R&D at Sanofi, also highlighted the potential of duvakitug to become a differentiated medicine for IBD patients. Both companies praised the collaborative efforts in advancing the drug’s development.

Duvakitug was generally well tolerated, with no significant safety concerns identified. The rates of treatment emergent adverse events were similar between the drug and placebo groups, with all reported adverse events being less than 5%. This safety profile, combined with the efficacy data, positions Teva and Sanofi to move forward with the next phase of clinical development.

While the efficacy and safety of duvakitug have not yet been evaluated by any regulatory authority, the positive Phase 2b results have set the stage for further clinical trials. Detailed results from the study are expected to be presented at a scientific forum in 2025, offering a clearer picture of the drug’s potential impact on the market and patient care.

Investors will be closely watching the progress of duvakitug as Teva and Sanofi continue their collaboration, with the aim of addressing the urgent need for new treatment options for those affected by ulcerative colitis and Crohn’s disease.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Crypto.com’s CEO Marszalek meets Trump at Mar-a-Lago
next post
FTC implements rule to ban hidden fees in live-event ticketing and short-term lodging

You may also like

BASF results down on impairments, restructuring

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Procter & Gamble to cut 7,000 jobs as part of broader restructuring

      June 6, 2025
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

      June 6, 2025
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

      June 5, 2025
    • This California startup is cleaning water and removing CO₂ from the atmosphere — all at a reduced cost

      June 5, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (504)
    • Stock (6,426)

    Latest News

    • Procter & Gamble to cut 7,000 jobs as part of broader restructuring
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

    Popular News

    • EUR/USD & EUR/GBP Analysis: High Volatility with Trends
    • South Korean ruling party to oppose Yoon’s impeachment

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy